Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

Steven M Horwitz; Robert S Negrin; Karl G Blume; Sheila Breslin; Monic J Stuart; Keith E Stockerl-Goldstein; Laura J Johnston; Ruby M Wong; Judith A Shizuru; Sandra J Horning

doi:10.1182/blood-2003-04-1257

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

Identifier:nobleid.org/w1/20260515/1102DBE1

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/1102DBE1.svg?ark=w1%2F20260515%2F1102DBE1)](https://nobleid.org/work/w1/20260515/1102DBE1)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Keith E Stockerl-Goldstein

Claim authorship of this work

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

Identifier:nobleid.org/w1/20260515/1102DBE1

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/1102DBE1.svg?ark=w1%2F20260515%2F1102DBE1)](https://nobleid.org/work/w1/20260515/1102DBE1)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Keith E Stockerl-Goldstein

Claim authorship of this work